Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
24
Feb |
PARI Pharma’s Altera Delivers Gilead’s Cayston, Approved By The U.S. FDA For The Improvement Of Respiratory Symptoms In Cystic Fibrosis PatientsCategory: Cystic Fibrosis | Leave a Comment |
Altera, which uses eFlow Technology, was cleared to market by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences’ Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S…
|
11
Sep |
UA Researchers Seek Safer Cystic Fibrosis TestCategory: Cystic Fibrosis | Leave a Comment |
Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers. Eric Snyder, PhD, assistant professor at the UA College of Pharmacy, is the principal investigator on the study, “Quantification of Exhaled Condensate Using Bronchoalveolar Lavage in Cystic Fibrosis.” Dr.
|
28
Apr |
Advancing Cystic Fibrosis TestingCategory: Cystic Fibrosis | Leave a Comment |
Three reports describing advances in cystic fibrosis genetic testing appear in the May 2009 issue of The Journal of Molecular Diagnostics. Cystic fibrosis is a hereditary disease that affects mucus secretions in the lungs, liver, pancreas, and intestines. Approximately 1 in 4000 children born in the United States is affected with cystic fibrosis.
|
25
Nov |
Prenatal Diagnostic Technology Allows Diagnosis Of Inherited Diseases Such As Cystic Fibrosis Caused By Single Gene MutationsCategory: Cystic Fibrosis | Leave a Comment |
Sequenom, Inc. (NASDAQ:SQNM), announced that breakthrough data from a collaborative project with The Chinese University of Hong Kong, supporting the noninvasive prenatal diagnosis of monogenic diseases, were published online today in the Early Edition of the Proceedings of the National Academy of Sciences.